Cumberland Pharmaceuticals (CPIX) Gross Profit (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of Gross Profit data on file, last reported at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 30.04% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $34.8 million (changed 0.34% YoY), and the FY2025 full-year result was $37.9 million, up 21.01% from the prior year.
• Gross Profit retreated to $7.2 million in Q1 2026, from $11.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $11.4 million in Q4 2025 to a low of $6.5 million in Q4 2022.
• A 5-year average of $8.4 million and a median of $8.3 million in 2022 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit jumped 48.61% in 2025 and sank 30.04% in 2026, its largest moves.
• Tracing CPIX's Gross Profit over 5 years: stood at $6.5 million in 2022, then grew by 20.85% to $7.8 million in 2023, then rose by 8.13% to $8.5 million in 2024, then surged by 35.21% to $11.4 million in 2025, then plunged by 37.07% to $7.2 million in 2026.
• Business Quant data shows CPIX's Gross Profit at $7.2 million in Q1 2026, $11.4 million in Q4 2025, and $7.3 million in Q3 2025.